Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Egalet, which is developing abuse-deterrent oral products for the treatment of pain, raised $50 million by offering 4.2 million shares at $12, the midpoint of the range of $11.00 to $13.00. Egalet plans to list on the NASDAQ under the symbol EGLT. Egalet...read more
Large deals from Santander Consumer USA (SC) and Rice Energy (RICE) posted pedestrian returns last week, while Care.com (CRCM) had the first substantial IPO pop of the year, jumping 43%. The site lifted the year’s average IPO return from 4% to a...read more
US IPO Recap: Revance jumps 68% in ten-IPO week
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Egalet prices upsized IPO at $12, the midpoint of the $11 to $13 range
Egalet, which is developing abuse-deterrent oral products for the treatment of pain, raised $50 million by offering 4.2 million shares at $12, the midpoint of the range of $11.00 to $13.00. Egalet plans to list on the NASDAQ under the symbol EGLT. Egalet...read more
12 US IPOs planned for the week of Feb 3
The following IPOs are expected to price this week: Argos Therapeutics (ARGS), which is developing immunotherapies for the treatment of cancer and HIV, plans to raise...read more
US IPO Recap: Care.com tends to a slow-starting IPO market
Large deals from Santander Consumer USA (SC) and Rice Energy (RICE) posted pedestrian returns last week, while Care.com (CRCM) had the first substantial IPO pop of the year, jumping 43%. The site lifted the year’s average IPO return from 4% to a...read more